HK1222865A1 - 通過施用 抑制劑抑制動脈粥樣硬化的方法 - Google Patents

通過施用 抑制劑抑制動脈粥樣硬化的方法

Info

Publication number
HK1222865A1
HK1222865A1 HK16111037.4A HK16111037A HK1222865A1 HK 1222865 A1 HK1222865 A1 HK 1222865A1 HK 16111037 A HK16111037 A HK 16111037A HK 1222865 A1 HK1222865 A1 HK 1222865A1
Authority
HK
Hong Kong
Prior art keywords
pcsk9
administering
inhibitor
methods
inhibiting atherosclerosis
Prior art date
Application number
HK16111037.4A
Other languages
English (en)
Inventor
William J Sasiela
Viktoria Gusarova
Anusch Peyman
Hans-Iudwig Schaefer
Uwe Schwahn
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP13305762.0A external-priority patent/EP2810955A1/en
Priority claimed from EP20130306436 external-priority patent/EP2862877A1/en
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HK1222865A1 publication Critical patent/HK1222865A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
HK16111037.4A 2013-06-07 2016-09-20 通過施用 抑制劑抑制動脈粥樣硬化的方法 HK1222865A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361832459P 2013-06-07 2013-06-07
EP13305762.0A EP2810955A1 (en) 2013-06-07 2013-06-07 Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
US201361892215P 2013-10-17 2013-10-17
EP20130306436 EP2862877A1 (en) 2013-10-18 2013-10-18 Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
US201461944855P 2014-02-26 2014-02-26
US201462002508P 2014-05-23 2014-05-23
PCT/US2014/041204 WO2014197752A1 (en) 2013-06-07 2014-06-06 Methods fo inhibting atherosclerosis by administering an inhibitor of pcsk9

Publications (1)

Publication Number Publication Date
HK1222865A1 true HK1222865A1 (zh) 2017-07-14

Family

ID=52008606

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111037.4A HK1222865A1 (zh) 2013-06-07 2016-09-20 通過施用 抑制劑抑制動脈粥樣硬化的方法

Country Status (12)

Country Link
US (3) US10494442B2 (zh)
EP (1) EP3004171B1 (zh)
JP (1) JP2016523847A (zh)
KR (1) KR20160024906A (zh)
CN (2) CN111920954A (zh)
AU (2) AU2014274844B2 (zh)
CA (1) CA2914721A1 (zh)
EA (1) EA201592267A1 (zh)
HK (1) HK1222865A1 (zh)
MX (1) MX2015016887A (zh)
TW (2) TW202021614A (zh)
WO (1) WO2014197752A1 (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
PL3395836T3 (pl) 2011-01-28 2021-12-13 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EP2756004B1 (en) 2011-09-16 2019-12-25 Regeneron Pharmaceuticals, Inc. INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) FOR USE IN REDUCING LIPOPROTEIN(a) LEVELS
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TW202021614A (zh) 2013-06-07 2020-06-16 法商賽諾菲生物技術公司 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
EP3068803B1 (en) 2013-11-12 2021-01-20 Sanofi Biotechnology Dosing regimens for use with pcsk9 inhibitors
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
WO2016010927A1 (en) * 2014-07-14 2016-01-21 Amgen Inc. Crystalline antibody formulations
MX2017000627A (es) 2014-07-16 2017-04-27 Sanofi Biotechnology Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
CA2995645A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
WO2017053734A1 (en) 2015-09-25 2017-03-30 Board Of Regents, The University Of Texas System Methods and compositions for treatment of atherosclerosis
CN105214087B (zh) * 2015-10-29 2017-12-26 陈敏 Pcsk9单克隆抗体在制备治疗炎症免疫性疾病药物中的应用
CN108697797A (zh) * 2016-02-17 2018-10-23 瑞泽恩制药公司 通过施用angptl3的抑制剂治疗或预防动脉粥样硬化的方法
BR112018076242A2 (pt) * 2016-06-24 2019-03-26 Hoffmann La Roche inibidores de pcsk9, pcsk9 inibido, composição farmacêutica, métodos para modular a atividade de pcsk9, para inibir a ligação de pcsk9 a ldlr, para aumentar a disponibilidade de ldlr, para reduzir um nível de ldl-c, para reduzir o nível sérico de ldl-c, para o tratamento de um distúrbio relacionado com colesterol, métodos para o tratamento de um distúrbio associado a um nível anormal de ldl-c, de uma condição associada a um nível elevado de ldl-c, de dislipidemia, de hipercolesterolemia, usos de um inibidor de pcsk9 e método para identificar um composto candidato como um inibidor de pcsk9 que liga um epítopo da seq id nº 1
EP3515950A4 (en) 2016-09-20 2020-10-28 Wuxi Biologics Ireland Limited. NEW ANTI-PCSK9 ANTIBODIES
MX2019012083A (es) 2017-04-13 2019-11-21 Cadila Healthcare Ltd Nueva vacuna de peptidos contra la pcsk9.
MX2021008533A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
WO2021058597A1 (en) * 2019-09-24 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject is at risk of developing arterial plaques

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993000807A1 (en) 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
AU2548097A (en) 1996-03-26 1997-10-17 Eli Lilly And Company Formulations of ob protein
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US20070224663A1 (en) 1997-03-07 2007-09-27 Human Genome Sciences, Inc. Human Secreted Proteins
US7030152B1 (en) 1997-04-02 2006-04-18 The Brigham And Women's Hospital, Inc. Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
JP4549529B2 (ja) 1998-01-30 2010-09-22 サイオス，インコーポレーテッド ペプチドまたはタンパク質の制御放出送達
EP1514933A1 (en) 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
US7129338B1 (en) 1999-07-08 2006-10-31 Research Association For Biotechnology Secretory protein or membrane protein
US7029895B2 (en) 1999-09-27 2006-04-18 Millennium Pharmaceuticals, Inc. 27411, a novel human PGP synthase
AU2001241461A1 (en) 2000-02-07 2001-08-14 Millennium Pharmaceuticals, Inc. Narc-1, novel subtilase-like homologs
WO2002020767A2 (en) 2000-09-08 2002-03-14 Massachusetts Institute Of Technology G-csf analog compositions and methods
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1471152A1 (en) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US20110313024A1 (en) 2004-08-20 2011-12-22 Leonid Beigelman RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20060147945A1 (en) 2005-01-06 2006-07-06 Edmonds Brian T Novel secreted proteins and their uses
ES2366974T3 (es) 2006-05-05 2011-10-27 Isis Pharmaceuticals, Inc. Compuestos y procedimientos para modular la expresión de sglt2.
WO2007134014A2 (en) 2006-05-05 2007-11-22 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of gcgr
ES2874149T3 (es) 2006-05-11 2021-11-04 Alnylam Pharmaceuticals Inc Composiciones y métodos para inhibir la expresión del gen PCSK9
EP2029103A2 (en) 2006-06-16 2009-03-04 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US20100150937A1 (en) 2006-11-07 2010-06-17 Sparrow Carl P Antagonists of pcsk9
US20100040611A1 (en) 2006-11-07 2010-02-18 Sparrow Carl P Antagonists of pcsk9
JP5588175B2 (ja) 2006-11-07 2014-09-10 メルク・シャープ・アンド・ドーム・コーポレーション Ｐｃｓｋ９のアンタゴニスト
CA2667989A1 (en) 2006-11-07 2008-11-06 Merck & Co., Inc. Antagonists of pcsk9
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
CN101679527A (zh) 2007-04-13 2010-03-24 诺瓦提斯公司 用于调节前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)的分子和方法
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
SG2013014352A (en) 2007-10-26 2014-09-26 Merck Sharp & Dohme Anti-pcsk9 and methods for treating lipid and cholesterol disorders
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
EP4238993A3 (en) 2008-04-11 2023-11-29 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
CN102159204B (zh) 2008-09-19 2015-04-01 辉瑞公司 稳定的液体抗体制剂
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
US20130064834A1 (en) * 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
CN104651408A (zh) 2009-06-15 2015-05-27 阿尔尼拉姆医药品有限公司 靶向pcsk9基因的脂质配制的dsrna
US20120114646A1 (en) 2009-06-18 2012-05-10 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
WO2011006000A1 (en) 2009-07-08 2011-01-13 Haiyan Liu Berberine derivatives useful for modulating lipid levels and their methods of synthesis
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
WO2011028938A1 (en) 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
EP2480576A4 (en) 2009-09-25 2013-04-10 Merck Sharp & Dohme ANTAGONISTS OF PCSK9
EP2483682A1 (en) 2009-10-02 2012-08-08 INSERM - Institut National de la Santé et de la Recherche Médicale Combination of spla2 activity and lp(a) cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
WO2011053783A2 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax213 and ax132 pcsk9 antagonists and variants
JP2013509191A (ja) 2009-10-30 2013-03-14 メルク・シャープ・エンド・ドーム・コーポレイション Ａｘ１およびａｘ１８９ｐｃｓｋ９アンタゴニストおよびバリアント
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
CN102844332B (zh) 2010-03-11 2015-08-19 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
GB201005005D0 (en) 2010-03-25 2010-05-12 Angeletti P Ist Richerche Bio New vaccine
KR101867279B1 (ko) 2010-10-06 2018-06-15 리제너론 파아마슈티컬스, 인크. 항―인터류킨―４ 수용체（ｉｌ－４ｒ） 항체를 함유하는 안정화된 제형
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
WO2012064792A2 (en) 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
EA201390929A1 (ru) 2010-12-22 2013-12-30 Дженентек, Инк. Антитела к pcsk9 и способы их применения
PL3395836T3 (pl) 2011-01-28 2021-12-13 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
KR20140006022A (ko) 2011-02-11 2014-01-15 아이알엠 엘엘씨 Pcsk9 길항제
AR088782A1 (es) 2011-04-29 2014-07-10 Sanofi Sa Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20140004122A1 (en) 2011-05-10 2014-01-02 Amgen Inc. Methods for treating or preventing cholesterol related disorders
JP2013023499A (ja) 2011-07-14 2013-02-04 Pfizer Inc 抗ｐｃｓｋ９抗体を用いた処置
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
EP2756004B1 (en) 2011-09-16 2019-12-25 Regeneron Pharmaceuticals, Inc. INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) FOR USE IN REDUCING LIPOPROTEIN(a) LEVELS
JP2015515279A (ja) 2012-04-19 2015-05-28 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 治療に反応する患者を同定するバイオマーカーおよびそのような患者の治療
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
NZ704771A (en) 2012-08-13 2018-02-23 Regeneron Pharma Anti-pcsk9 antibodies with ph-dependent binding characteristics
EP2703009A1 (en) 2012-08-31 2014-03-05 Sanofi Combination treatments involving antibodies to human PCSK9
EP2703008A1 (en) 2012-08-31 2014-03-05 Sanofi Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
EP2706070A1 (en) 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI682780B (zh) 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
TW202021614A (zh) 2013-06-07 2020-06-16 法商賽諾菲生物技術公司 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
KR20230119045A (ko) 2013-10-11 2023-08-14 사노피 바이오테크놀로지 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도
EP3068803B1 (en) 2013-11-12 2021-01-20 Sanofi Biotechnology Dosing regimens for use with pcsk9 inhibitors
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
EA201691320A1 (ru) 2014-02-14 2016-11-30 Ридженерон Фармасьютикалз, Инк. Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
US20150283236A1 (en) 2014-03-17 2015-10-08 Marie Baccara-Dinet Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
KR20220157516A (ko) 2014-03-17 2022-11-29 사노피 바이오테크놀로지 심혈관 위험을 감소시키는 방법
US20160137746A1 (en) 2014-07-16 2016-05-19 Sanofi Biotechnology Methods for treating high cardiovascular risk patients with hypercholesterolemia
MX2017000627A (es) 2014-07-16 2017-04-27 Sanofi Biotechnology Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
CA2995645A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis

Also Published As

Publication number Publication date
WO2014197752A8 (en) 2015-12-23
AU2020201191A1 (en) 2020-03-05
KR20160024906A (ko) 2016-03-07
TW202021614A (zh) 2020-06-16
AU2014274844A1 (en) 2016-01-21
AU2014274844B2 (en) 2019-11-28
WO2014197752A1 (en) 2014-12-11
JP2016523847A (ja) 2016-08-12
US10995150B2 (en) 2021-05-04
US20200071422A1 (en) 2020-03-05
AU2014274844A8 (en) 2016-02-25
TW201534324A (zh) 2015-09-16
CN111920954A (zh) 2020-11-13
EP3004171B1 (en) 2021-10-13
MX2015016887A (es) 2016-07-26
EP3004171A1 (en) 2016-04-13
US20180244801A1 (en) 2018-08-30
EA201592267A1 (ru) 2016-04-29
CA2914721A1 (en) 2014-12-11
US20160115246A1 (en) 2016-04-28
CN105705521A (zh) 2016-06-22
US10494442B2 (en) 2019-12-03

Similar Documents

Publication Publication Date Title
HK1222865A1 (zh) 通過施用 抑制劑抑制動脈粥樣硬化的方法
IL279682A (en) Benzoquinolone compounds as VMAT2 inhibitors
ZA201602245B (en) Inhibitors of kras g12c
HK1213251A1 (zh) 作為突變 抑制劑的 -嘧啶- -基-噁唑烷- -酮化合物
HK1222387A1 (zh) 作為 抑制劑的芳基吡咯並吡啶衍生的化合物
LT3080100T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
EP2948450A4 (en) METALLOENZYMINHIBITORVERBINDUNGEN
EP3008051A4 (en) Metalloenzyme inhibitor compounds
HK1219271A1 (zh) 作爲 抑制劑的化合物和組合物
GB201410735D0 (en) Method of inhibiting DYRK1B
HK1222339A1 (zh) 金屬-β-內酰胺酶的抑制劑
EP3632467C0 (en) INHIBITORS OF COMPLEMENT FACTOR H
HK1221645A1 (zh) 的苯並喹啉抑制劑
HK1214252A1 (zh) 作為凝血酶抑制劑的鹵代吡唑
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
HK1221159A1 (zh) 轉移抑制劑
EP2959896A4 (en) INHIBITOR OF PHOSPHORYLATION OF PROTEIN T
GB201312311D0 (en) Uses of enzyme inhibitors
GB201320835D0 (en) HIF inhibitors
GB201308117D0 (en) Inhibitor of calcifying disorders